Article
Sulindac and sulindac metabolites in nipple aspirate fluid and effect on drug targets in a phase I trial.
Cancer prevention research (Philadelphia, Pa.) - 1 Jan 2010
Thompson Patricia A, Hsu Chiu-Hsieh, Green Sylvan, Stopeck Alison T, Johnson Karen, Alberts David S, Chow H-H Sherry
Abstract excerpt
Regular use of nonsteroidal anti-inflammatory drugs (NSAID) has been associated with reduced risk of breast cancer. Sulindac, a nonselective NSAID with both cyclooxygenase-2-dependent and -independent activities, is a candidate for breast chemoprevention. We conducted a phase Ib trial in 30 women at increased risk for breast cancer to evaluate the breast tissue distribution of sulindac at two dose levels (150 mg...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.